Drug profile · INN
rilpivirine
EDURANT
rilpivirine (EDURANT) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — rilpivirine
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 0
- Programs
- 6
- Data quality
- 0.84
Quick answer
rilpivirine (EDURANT) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Primary target: Human immunodeficiency virus type 1 reverse transcriptase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rilpivirine?
rilpivirine (EDURANT) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rilpivirine?
EDURANT is a marketed brand name for rilpivirine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rilpivirine?
rilpivirine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.